Response to Letter to Editor Regarding “Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma”

ElsevierVolume 26, Issue 12, December 2020, Pages e335-e336Biology of Blood and Marrow TransplantationPrevious article in issueNext article in issue

Recommended articlesCiting articles (0)

© 2020 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.

Recommended articlesCiting articlesArticle Metrics

留言 (0)

沒有登入
gif